Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - the SPECTRA Study
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Jan 8, 2025
Trial Information
Current as of November 11, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The SPECTRA Study is an important research project aimed at understanding the health and well-being of transgender and gender-diverse individuals in Switzerland who are receiving gender-affirming therapies. This study will look at people aged 16 and older, including those who are just starting their transition, those who have completed it, and even those who have decided to stop their transition. The main goal is to find out what factors affect the health and happiness of these individuals during their journey.
If you or someone you know is interested in participating, you must be at least 16 years old and have a diagnosed condition related to gender incongruence. Participants will fill out online questionnaires about their feelings and experiences, provide biological samples for lab tests, and have regular health check-ups related to hormone treatments and other areas. While the study is not yet recruiting, it aims to gather valuable insights that could improve care and support for transgender and gender-diverse individuals in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 16 years and above.
- • Established diagnosis of gender incongruence
- • Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy
- Exclusion Criteria:
- • Unable to give informed consent
- • Missing commitment or ability to study protocol adherence
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Switzerland
Lucerne, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported